Immunosuppressive drug azathioprine reduces aneurysm progression through inhibition of Rac1 and c-Jun-Terminal-N-Kinase in endothelial cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 10, 2013, Pages 2380-2388

  Marinković, Goran ^a   Hibender, Stijntje ^a   Hoogenboezem, Mark ^a   Van Broekhoven, Amber ^a   Girigorie, Arginell F ^a   Bleeker, Natascha ^a   Hamers, Anouk A J ^a   Stap, Jan ^a   Van Buul, Jaap D ^a   De Vries, Carlie J M ^a   De Waard, Vivian ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

aneurysm; endothelium; inflammation

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; AZATHIOPRINE; INTERLEUKIN 12; MERCAPTOPURINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN C JUN; RAC1 PROTEIN; RANTES; STRESS ACTIVATED PROTEIN KINASE; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL TRANSPORT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; LOW DRUG DOSE; MONOCYTE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SCORING SYSTEM;

ANEURYSM; ENDOTHELIUM; INFLAMMATION;

6-MERCAPTOPURINE; ANGIOTENSIN II; ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTIC ANEURYSM; AORTIC RUPTURE; APOLIPOPROTEINS E; AZATHIOPRINE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, KNOCKOUT; MONOCYTES; NEUROPEPTIDES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84885067889     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301394     Document Type: Article

References (52)

1. Svensjö S, Björck M, Gürtelschmid M, Djavani Gidlund K, Hellberg A, Wanhainen A. Low prevalence of abdominal aortic aneurysm among 65-year-old Swedish men indicates a change in the epidemiology of the disease. Circulation. 2011;124:1118-1123
2. Guessous I, Periard D, Lorenzetti D, Cornuz J, Ghali WA. The efficacy of pharmacotherapy for decreasing the expansion rate of abdominal aortic aneurysms: A systematic review and meta-Analysis. PLoS One. 2008;3:e1895
3. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: A population-based case-control study. Lancet. 2006;368:659-665
4. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: Doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation. 2009;119:2209-2216
5. Rughani G, Robertson L, Clarke M. Medical treatment for small abdominal aortic aneurysms. Cochrane Database Syst Rev. 2012;9:CD009536
6. Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM, Powell JT. Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg. 2010;52:1-4
7. Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Effects of statin therapy on abdominal aortic aneurysm growth: A meta-Analysis and meta-regression of observational comparative studies. Eur J Vasc Endovasc Surg. 2012;44:287-292
8. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-994
9. de Waard V, Bot I, De Jager SC, Talib S, Egashira K, De Vries MR, Quax PH, Biessen EA, van Berkel TJ. Systemic MCP1/CCR2 blockade and leukocyte specific MCP1/CCR2 inhibition affect aortic aneurysm formation differently. Atherosclerosis. 2010;211:84-89
10. Nahrendorf M, Keliher E, Marinelli B, Leuschner F, Robbins CS, Gerszten RE, Pittet MJ, Swirski FK, Weissleder R. Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler Thromb Vasc Biol. 2011;31:750-757
11. Rush C, Nyara M, Moxon JV, Trollope A, Cullen B, Golledge J. Whole genome expression analysis within the angiotensin II-Apolipoprotein E deficient mouse model of abdominal aortic aneurysm. BMC Genomics. 2009;10:298
12. King VL, Trivedi DB, Gitlin JM, Loftin CD. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol. 2006;26:1137-1143
13. Lawrence DM, Singh RS, Franklin DP, Carey DJ, Elmore Jr. Rapamycin suppresses experimental aortic aneurysm growth. J Vasc Surg. 2004;40:334-338
14. Esteban V, Méndez-Barbero N, Jiménez-Borreguero LJ, Roqué M, Novensá L, García-Redondo AB, Salaices M, Vila L, Arbonés ML, Campanero MR, Redondo JM. Regulator of calcineurin 1 mediates pathological vascular wall remodeling. J Exp Med. 2011;208:2125-2139
15. Reilly JM, Savage EB, Brophy CM, Tilson MD. Hydrocortisone rapidly induces aortic rupture in a genetically susceptible mouse. Arch Surg. 1990;125:707-709
16. Lindeman JH, Rabelink TJ, van Bockel JH. Immunosuppression and the abdominal aortic aneurysm: Doctor Jekyll or Mister Hyde? Circulation. 2011;124:e463-e465
17. Yoo YG, Na TY, Yang WK, Kim HJ, Lee IK, Kong G, Chung JH, Lee MO. 6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1alpha resulting in new vessel formation. Oncogene. 2007;26:3823-3834
18. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-Analysis. Lancet. 2012;379:1393-1402
19. Redondo-Horcajo M, Romero N, Martínez-Acedo P, Martínez-Ruiz A, Quijano C, Lourenço CF, Movilla N, Enríquez JA, Rodríguez-Pascual F, Rial E, Radi R, Vázquez J, Lamas S. Cyclosporine A-induced nitration of tyrosine 34 MnSOD in endothelial cells: Role of mitochondrial superoxide. Cardiovasc Res. 2010;87:356-365
20. de Waard V, Arkenbout EK, Vos M, Mocking AI, Niessen HW, Stooker W, De Mol BA, Quax PH, Bakker EN, VanBavel E, Pannekoek H, De Vries CJ. TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. Am J Pathol. 2006;168:2027-2035
21. Pires NM, Pols TW, De Vries MR, van Tiel CM, Bonta PI, Vos M, Arkenbout EK, Pannekoek H, Jukema JW, Quax PH, De Vries CJ. Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation. 2007;115:493-500
22. Pols TW, Bonta PI, Pires NM, Otermin I, Vos M, De Vries MR, van Eijk M, Roelofsen J, Havekes LM, Quax PH, van Kuilenburg AB, De Waard V, Pannekoek H, De Vries CJ. 6-mercaptopurine inhibits atherosclerosis in apolipoprotein e. 3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages. Arterioscler Thromb Vasc Biol. 2010;30:1591-1597
23. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145
24. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, Hoshii Y, Tanaka N, Ricci R, Ishihara T, Esato K, Hamano K, Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-Terminal kinase. Nat Med. 2005;11:1330-1338
25. Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, Strand D, Tanaka S, Galle PR, Bustelo XR, Neurath MF. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol. 2006;176:640-651
26. Kanaji N, Nelson A, Wang X, Sato T, Nakanishi M, Gunji Y, Basma H, Michalski J, Farid M, Rennard SI, Liu X. Differential roles of JNK, ERK1/2, and p38 mitogen-Activated protein kinases on endothelial cell tissue repair functions in response to tumor necrosis factor-α. J Vasc Res. 2013;50:145-156
27. Cassis LA, Rateri DL, Lu H, Daugherty A. Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol. 2007;27:380-386
28. Barisione C, Charnigo R, Howatt DA, Moorleghen JJ, Rateri DL, Daugherty A. Rapid dilation of the abdominal aorta during infusion of angiotensin II detected by noninvasive high-frequency ultrasonography. J Vasc Surg. 2006;44:372-376
29. Saraff K, Babamusta F, Cassis LA, Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1621-1626
30. Torsney E, Pirianov G, Charolidi N, Shoreim A, Gaze D, Petrova S, Laing K, Meisinger T, Xiong W, Baxter BT, Cockerill GW. Elevation of plasma high-density lipoproteins inhibits development of experimental abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2012;32:2678-2686
31. Murasawa S, Matsubara H, Mori Y, Masaki H, Tsutsumi Y, Shibasaki Y, Kitabayashi I, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Iba S, Iwasaka T. Angiotensin II initiates tyrosine kinase Pyk2-dependent signalings leading to activation of Rac1-mediated c-Jun NH2-Terminal kinase. J Biol Chem. 2000;275:26856-26863
32. Fan J, Li X, Yan YW, Tian XH, Hou WJ, Tong H, Bai SL. Curcumin attenuates rat thoracic aortic aneurysm formation by inhibition of the c-Jun N-Terminal kinase pathway and apoptosis. Nutrition. 2012;28:1068-1074
33. Pirianov G, Torsney E, Howe F, Cockerill GW. Rosiglitazone negatively regulates c-Jun N-Terminal kinase and toll-like receptor 4 proinflammatory signalling during initiation of experimental aortic aneurysms. Atherosclerosis. 2012;225:69-75
34. Takagi Y, Ishikawa M, Nozaki K, Yoshimura S, Hashimoto N. Increased expression of phosphorylated c-Jun amino-Terminal kinase and phosphorylated c-Jun in human cerebral aneurysms: Role of the c-Jun amino-Terminal kinase/c-Jun pathway in apoptosis of vascular walls. Neurosurgery. 2002;51:997-1002; discussion 1002
35. Laaksamo E, Tulamo R, Baumann M, Dashti R, Hernesniemi J, Juvela S, Niemelä M, Laakso A. Involvement of mitogen-Activated protein kinase signaling in growth and rupture of human intracranial aneurysms. Stroke. 2008;39:886-892
36. DiMusto PD, Lu G, Ghosh A, Roelofs KJ, Sadiq O, McEvoy B, Su G, Laser A, Bhamidipati CM, Ailawadi G, Henke PK, Eliason JL, Upchurch GR Jr. Increased JNK in males compared with females in a rodent model of abdominal aortic aneurysm. J Surg Res. 2012;176:687-695
37. Hoh BL, Hosaka K, Downes DP, Nowicki KW, Fernandez CE, Batich CD, Scott EW. Monocyte chemotactic protein-1 promotes inflammatory vascular repair of murine carotid aneurysms via a macrophage inflammatory protein-1α and macrophage inflammatory protein-2-dependent pathway. Circulation. 2011;124:2243-2252
38. Moehle CW, Bhamidipati CM, Alexander MR, Mehta GS, Irvine JN, Salmon M, Upchurch GR Jr, Kron IL, Owens GK, Ailawadi G. Bone marrow-derived MCP1 required for experimental aortic aneurysm formation and smooth muscle phenotypic modulation. J Thorac Cardiovasc Surg. 2011;142:1567-1574
39. Iida Y, Xu B, Xuan H, Glover KJ, Tanaka H, Hu X, Fujimura N, Wang W, Schultz JR, Turner CR, Dalman RL. Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression. Arterioscler Thromb Vasc Biol. 2013;33:718-726
40. Boiardi L, Vaglio A, Nicoli D, Farnetti E, Palmisano A, Pipitone N, Maritati F, Casali B, Martorana D, Moroni G, Gallelli B, Buzio C, Salvarani C. CC chemokine receptor 5 polymorphism in chronic periaortitis. Rheumatology (Oxford). 2011;50:1025-1032
41. Ghilardi G, Biondi ML, Battaglioli L, Zambon A, Guagnellini E, Scorza R. Genetic risk factor characterizes abdominal aortic aneurysm from arterial occlusive disease in human beings: CCR5 Delta 32 deletion. J Vasc Surg. 2004;40:995-1000
42. Sandford B, Bown M, London N, Sayers R. The role of the CCR5 Delta32 polymorphism in abdominal aortic aneurysms. Int J Immunogenet. 2009;36:199-205
43. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000:CD000067
44. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000:CD000545
45. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007:CD000478
46. Kaibuchi K, Kuroda S, Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem. 1999;68:459-486
47. Chung AW, Yang HH, Radomski MW, van Breemen C. Long-Term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and-9. Circ Res. 2008;102:e73-e85
48. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23:483-488
49. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, Thompson RW. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649
50. Xiong W, Knispel RA, Dietz HC, Ramirez F, Baxter BT. Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. J Vasc Surg. 2008;47:166-172; discussion 172
51. Meijer CA, van Bockel JH, Lindeman JH. Doxycycline to inhibit abdominal aortic aneurysm progression. In: Greenhalgh RM, ed. Vascular and Endovascular Challenges. London: Biba; 2013:234-242
52. Xie X, Lu H, Moorleghen JJ, Howatt DA, Rateri DL, Cassis LA, Daugherty A. Doxycycline does not influence established abdominal aortic aneurysms in angiotensin II-infused mice. PLoS One. 2012;7:e46411